Who makes aQIV or aTIV?

aQIV or aTIV is developed by Seqirus.

Last reviewed 2026-04-19 · How we verify

aQIV or aTIV

Seqirus · Phase 3 active Biologic

At a glance

Generic name	aQIV or aTIV
Also known as	Fluad Tetra/Quadrivalent or Fluad
Sponsor	Seqirus
Modality	Biologic
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

aQIV or aTIV CI brief — competitive landscape report
aQIV or aTIV updates RSS · CI watch RSS
Seqirus portfolio CI